Lanean...

Hydroxyurea induces fetal hemoglobin by the nitric oxide–dependent activation of soluble guanylyl cyclase

Hydroxyurea treatment of patients with sickle-cell disease increases fetal hemoglobin (HbF), which reduces hemoglobin S polymerization and clinical complications. Despite its use in the treatment of myeloproliferative diseases for over 30 years, its mechanism of action remains uncertain. Recent stud...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Cokic, Vladan P., Smith, Reginald D., Beleslin-Cokic, Bojana B., Njoroge, Joyce M., Miller, Jeffery L., Gladwin, Mark T., Schechter, Alan N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2003
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC151872/
https://ncbi.nlm.nih.gov/pubmed/12531879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI200316672
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!